Human monoclonal antibodies (mAbs)--highly specific, identical, infection-fighting proteins produced in large quantities in the lab in cell lines that are derived from a single cell--against influenza ...

The COVID-19 pandemic has reminded us that no country is immune to the threat posed by emerging infectious diseases. Ensuring prompt, affordable, and equitable global access to potentially life-saving ...

Monoclonal antibodies (mAbs) make up one of the most important classes of advanced biotherapies. To find out about the current challenges and advances in the production of mAbs, GEN talked with Lukas ...

Company Cites Platform’s Advantages from Discovery through Commercial Manufacturing All currently marketed therapeutic Mabs are produced in mammalian cell cultures, a process that is prohibitively ...

The development of monoclonal antibodies—human immune proteins that can provide rapid, passive protection against some infectious diseases—is progressing quickly and holds great promise for expanding ...

Monoclonal antibodies (mAbs) have been a key therapeutic option for non-communicable diseases for decades, and a small number of mAbs have helped treat infectious diseases, including COVID-19. The ...

Organizations across the public and private sectors must join forces to make global access to transformative monoclonal antibody products a priority and a reality. The groups highlight four areas of ...

Monoclonal antibodies (mAbs) can achieve unparalleled affinity and specificity for a wide range of biomolecules, making the reagents critical to both basic and clinical research. The vast majority of ...

Monoclonal antibodies target specific disease molecules. They can help treat cancer, autoimmune disorders, and infectious diseases. Discover what you should know about this therapy. Monoclonal ...

Human monoclonal antibodies against influenza can be rapidly produced in the lab, according to a new report. Using cells drawn from volunteers inoculated with seasonal influenza vaccine, the ...